SAM
VKTX icon

Smartleaf Asset Management’s Viking Therapeutics VKTX Stock Holding History

Smartleaf Asset Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.07K Hold
204
– – ﹤0.01% 2451
2026
Q1 		$6.1K Sell
204
-4
-2% -$129 ﹤0.01% 2574
2025
Q4 		$7.35K Buy
208
+127
+157% +$4.5K ﹤0.01% 2530
2025
Q3 		$2.09K Buy
+81
New +$2.42K ﹤0.01% 2608
2025
Q2 		– Sell
-83
Closed -$2.13K – 2981
2025
Q1 		$2.13K Buy
83
+7
+9% +$221 ﹤0.01% 2462
2024
Q4 		$3.02K Buy
76
+64
+533% +$3.65K ﹤0.01% 2413
2024
Q3 		$739 Sell
12
-206
-94% -$12.1K ﹤0.01% 2721
2024
Q2 		$11.1K Buy
+218
New +$14.3K ﹤0.01% 1357

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Smartleaf Asset Management's VKTX Position: Q2 2026 in Review

Smartleaf Asset Management held its Viking Therapeutics (VKTX) position steady in Q2 2026 at 204 shares worth $8.07K. The position accounts for ﹤0.01% of the portfolio, ranked #2451.

Smartleaf Asset Management first reported a position in VKTX in Q2 2024 and has held it in 8 quarters since. The position peaked at $11.1K in Q2 2024. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Smartleaf Asset Management held 204 shares of Viking Therapeutics worth $8.07K as of Q2 2026.
  • Smartleaf Asset Management left its Viking Therapeutics share count unchanged in Q2 2026.
  • Viking Therapeutics made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q2 2026, its #2451 holding.
  • Smartleaf Asset Management first reported a position in Viking Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • Smartleaf Asset Management's Viking Therapeutics position peaked at $11.1K in Q2 2024.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Smartleaf Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.